newsfilter
← Latest News
GlobeNewswire·

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

DOVER, Del., March 12, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced the